Main Article Content
Personalized medicine, clinical trials, NNT benefit/harm, drug regulation, cost - effectiveness
Abrahamyan et al 1 have provided a valuable summary of innovative methods that may be applied in the design of clinical trials for small populations such as those suffering from rare disorders. In that context they point out the many limitations encountered in relying upon traditional randomized trial designs, both with respect to the challenges in providing power to assess small treatment effects, and the consequent dilemma for payers in determining economic and/or social value from outcomes measure d in such studies.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:104 5 - 57.
3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981 - 92.
4. Garner D . Introducing ‘more patient reality’ into NHS spending decisions. Jan 24, 2013. http://www.york.ac.uk/ news - and - events/news/2013/research/nhs - spending - research/ (August 24, 2013)
5. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold, CHE Research Paper 81, University of York, 2013. http://www.york.ac.uk/me dia/che/documents/pa pers/researchpapers/CHERP81_Methods_estima tion_NICE_costeffectiveness_threshold.pdf (August 24, 2013)